Press Releases

Aug 04, 2021
CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Therapies in CAR T Naïve Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Next CD19
Jun 21, 2021
Veteran pharmaceutical executive with proven cell and gene therapy development experience in Asia , formerly of WuXi AppTec Shanghai and the joint venture JW Therapeutics SOUTH SAN FRANCISCO, Calif. & BOSTON & SHANGHAI --(BUSINESS WIRE)--Jun. 21, 2021-- Allogene Overland Biopharm (Allogene
Jun 04, 2021
ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrated Six Month Complete
Displaying 1 - 10 of 25
Print Page
Email Alerts
RSS Feeds
Investor Contacts